Search

Your search keyword '"Yutiq (Medication)"' showing total 273 results
Start Over Descriptor "Yutiq (Medication)"
273 results on '"Yutiq (Medication)"'

52. Alimera Acquires U.S. Commercial Rights to YUTIQ(R)

Subjects
Fluocinolone acetonide, Financial statements, Fluocinolone, Banking, finance and accounting industries, Business, Yutiq (Medication)
Abstract

Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023 Alimera projects at least $100 million of consolidated net revenue and over $20 million of Adjusted EBITDA* in [...]

Published
2023

53. EyePoint Pharmaceuticals offloads its commercially-available eye implant for $82.5 million plus royalties

Subjects
Fluocinolone acetonide, Fluocinolone, Drug approval, Royalties, General interest, News, opinion and commentary, Yutiq (Medication)
Abstract

EyePoint Pharmaceuticals Inc EYPT has agreed to sell Yutiq (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences Inc ALIM. Yutiq is a treatment for chronic non-infectious uveitis affecting the posterior [...]

Published
2023

57. Q1 2022 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration, Patient compliance, Business, Eylea (Medication), Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Josh, and I'll be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals First Quarter [...]

Published
2022

58. EyePoint Pharmaceuticals Inc at B Riley Neuro & Ophthalmology Conference (Virtual) - Final

Subjects
Fluocinolone acetonide -- Conferences, meetings and seminars, Ophthalmology -- Conferences, meetings and seminars, Fluocinolone -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Business, Eylea (Medication), Yutiq (Medication)
Abstract

Presentation MAYANK MAMTANI, ANALYST, B. RILEY SECURITIES, INC.: Good morning. Welcome back, everyone, to day two of B. Riley Neuro and Ophthalmology Conference. We thank you all for being part [...]

Published
2022

61. EyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQ

Subjects
Eye diseases, Leases, Commercial buildings, General interest, News, opinion and commentary, Yutiq (Medication)
Abstract

WATERTOWN: EyePoint Pharmaceuticals, Inc. has issued the following news release: EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of [...]

Published
2023

62. EyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQ

Subjects
Eye diseases -- Care and treatment, Leases, Commercial buildings, Real estate industry, Yutiq (Medication)
Abstract

(GlobeNewswire) - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that [...]

Published
2023

64. EyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQ

Subjects
Eye diseases, Leases, Commercial buildings, Banking, finance and accounting industries, Business, Yutiq (Medication)
Abstract

- State-of-the-art cGMP manufacturing facility to be built in Northbridge, Massachusetts - - Awarded $1.9 million of state and local grants with rent commencing in second half of 2024 - [...]

Published
2023

65. EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines

Subjects
Eye diseases, Patient compliance, Prospective payment systems (Medical care), General interest, News, opinion and commentary, Dexycu (Medication), Yutiq (Medication)
Abstract

WATERTOWN: EyePoint Pharmaceuticals, Inc. has issued the following press release: EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of [...]

Published
2023

66. EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines

Subjects
Patient compliance, Prospective payment systems (Medical care), Banking, finance and accounting industries, Business, Dexycu (Medication), Yutiq (Medication)
Abstract

- Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 - - Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for [...]

Published
2023

67. Q4 2021 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration, Patient compliance, Business, Eylea (Medication), Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Jonathan, and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Fourth [...]

Published
2022

68. Q3 2021 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
Business, American Academy of Ophthalmology, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good day, and thank you for standing by. Welcome to the EyePoint Third Quarter 2021 Financial Results Conference Call. (Operator Instructions) Please be advised that today's conference is [...]

Published
2021

69. EyePoint Pharma Sells U.S. Rights to Eye Med to Become Pure Play Drug Developer

Author

Vinluan, Frank

Subjects
Diabetic retinopathy, Macular degeneration, Yutiq (Medication)
Abstract

https://medcitynews.com/2023/05/eyepoint-pharma-sells-u-s-rights-to-eye-med-to-become-pure-play-drug-developer/ By selling U.S. rights to Yutiq, EyePoint Pharmaceuticals gets $75 million cash to support its drug pipeline. The company’s lead product candidate is in mid-stage development for wet age-related [...]

Published
2023

70. Ocumension Therapeutics invests $15.7 million in EyePoint Pharmaceuticals

Subjects
Pharmaceuticals and cosmetics industries, Dexycu (Medication), Yutiq (Medication)
Abstract

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company, has made a $15.7 million equity investment [...]

Published
2021

73. Q2 2021 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Norma, and I'll be your conference operator today. At this time, I would like to welcome everyone to EyePoint Pharmaceuticals' Second Quarter 2021 [...]

Published
2021

74. EyePoint sees Q3 revenue $5.5M-$5.9M, consensus $7.6M

Subjects
COVID-19, Company earnings/profit, Business, News, opinion and commentary, Dexycu (Medication), Yutiq (Medication)
Abstract

'We were pleased to see the continued return of customer demand for both YUTIQ and DEXYCU during the third quarter of 2020, as more healthcare facilities re-opened for business and [...]

Published
2020

75. EyePoint presents data supporting YUTIQ at ASRS Annual Meeting

Subjects
Fluocinolone, Business, News, opinion and commentary, Yutiq (Medication)
Abstract

EyePoint Pharmaceuticals announced the presentation of data supporting YUTIQ 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye. The data were presented in two [...]

Published
2020

76. EyePoint sees no disruptionds to YUTIQ, DEXYCU supply chains

Subjects
Business logistics, Produce industry, Business, News, opinion and commentary, Dexycu (Medication), Yutiq (Medication)
Abstract

There have been no disruptions to the supply chains for YUTIQ and DEXYCU and the Company continues to produce finished product for commercial [...]

Published
2020

77. EyePoint says YUTIQ, DEXYCU supply chains have not been interrupted

Subjects
Medical offices, Business logistics, Physicians, Raw materials, Business, News, opinion and commentary, Dexycu (Medication), Yutiq (Medication)
Abstract

The company said, 'EyePoint is committed to providing uninterrupted access to our products during the COVID-19 pandemic for those patients who are in essential need of treatment. Our supply chains [...]

Published
2020

79. EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments

Subjects
Macular degeneration -- Care and treatment, Company earnings/profit, Banking, finance and accounting industries, Business, Dexycu (Medication), Yutiq (Medication)
Abstract

WATERTOWN, Mass., Aug 03, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NasdaqGM:EYPT), EQNX::TICKER_END - First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration [...]

Published
2022

80. Q1 2021 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Welcome to the EyePoint First Quarter 2021 Financial Results Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like [...]

Published
2021

81. Q4 2020 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Kevin, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the EyePoint Pharmaceuticals Fourth Quarter and [...]

Published
2021

82. EyePoint Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) - Final

Subjects
Cowen and Company L.L.C. -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Securities industry, Business, Yutiq (Medication)
Abstract

Presentation KENNETH CHARLES CACCIATORE, MD & SENIOR RESEARCH ANALYST, COWEN AND COMPANY, LLC, RESEARCH DIVISION: Great. Thanks, everyone, for joining the EyePoint fireside chat. Really happy to have both Nancy [...]

Published
2021

83. EyePoint Pharmaceuticals and OcuMension Therapeutics Announced Approval of New Drug Application by China's NMPA for YUTIQ(r) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Subjects
Fluocinolone acetonide, Uveitis -- Drug therapy, Ophthalmology, Fluocinolone, Business, international, Yutiq (Medication)
Abstract

WATERTOWN: EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, and OcuMension Therapeutics (HKSE: [...]

Published
2022

84. EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Subjects
Yutiq (Medication)
Abstract

ENPNewswire-June 22, 2022--EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of [...]

Published
2022

85. EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Subjects
Fluocinolone acetonide, Ophthalmology, Uveitis -- Drug therapy, Fluocinolone, Banking, finance and accounting industries, Business, Yutiq (Medication)
Abstract

WATERTOWN, Jun 21, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NasdaqGM:EYPT),(HKSE:1477), EQNX::TICKER_END EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the [...]

Published
2022

87. EyePoint Pharmaceuticals Inc to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD - Final

Subjects
Drugs -- Vehicles, Eye diseases, Patient compliance, Antineoplastic agents, Drug delivery systems, Antimitotic agents, Business, Eylea (Medication), Yutiq (Medication), Iluvien (Medication), Avastin (Medication)
Abstract

Presentation OPERATOR: Good morning, and welcome to the EyePoint Pharmaceuticals' Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD. (Operator Instructions) Please note, this event [...]

Published
2020

88. Q3 2020 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration, Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Bridget, and I'll be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Third Quarter [...]

Published
2020

89. Q3 2020 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration, Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Bridget, and I'll be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Third Quarter [...]

Published
2020

90. Q2 2020 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration, Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Josh, and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Second [...]

Published
2020

91. Q1 2020 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Shannon, and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals First [...]

Published
2020

92. Q1 2020 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
Finance, Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Shannon, and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals First [...]

Published
2020

93. Q1 2020 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
Finance, Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Shannon, and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals First [...]

Published
2020

94. Q4 2019 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration, Patient compliance, Finance, Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Sarah, and I'll be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Fourth Quarter [...]

Published
2020

95. Q4 2019 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration, Patient compliance, Finance, Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Sarah, and I'll be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Fourth Quarter [...]

Published
2020

96. Q4 2019 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration, Patient compliance, Finance, Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Sarah, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Eyepoint Pharmaceuticals Fourth Quarter [...]

Published
2020

97. EyePoint announces addition of DEXYCU, YUTIQ to VA federal supply schedule

Subjects
Beneficiaries, Business, News, opinion and commentary, Dexycu (Medication), Yutiq (Medication)
Abstract

EyePoint Pharmaceuticals announced that it has signed an interim agreement with the U.S. Department of Veteran Affairs for DEXYCU and YUTIQ to be included on the Federal Supply Schedule, providing [...]

Published
2019

98. EyePoint announces J-Code for Yutiq is now in effect

Subjects
Medicaid, Medicare, Uveitis, Business, News, opinion and commentary, Yutiq (Medication)
Abstract

EyePoint announced that the company's permanent and specific J-Code for Yutiq 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye is now in effect. [...]

Published
2019

99. EyePoint presents 'positive' data on Yutiq at ASRS meeting

Subjects
Eye diseases, Professional associations, Uveitis, Business, News, opinion and commentary, Yutiq (Medication)
Abstract

EyePoint Pharmaceuticals announced the presentation of data supporting the company's Yutiq 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye. The data were presented [...]

Published
2019

100. EyePoint announces early assignment of reimbursement J-Code for YUTIQ

Subjects
Medicaid, Medicare, Uveitis, Business, News, opinion and commentary, Yutiq (Medication)
Abstract

EyePoint Pharmaceuticals announced that the Centers for Medicare and Medicaid Services has assigned a specific and permanent reimbursement J-code, J7314, through the Healthcare Common Procedure Coding System for YUTIQ 0.18 [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results